Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
Public ClinicalTrials.gov record NCT00826280. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI) in Subjects Administered Regadenoson
Study identification
- NCT ID
- NCT00826280
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Enrollment
- 347 participants
Conditions and interventions
Conditions
Interventions
- regadenoson Drug
- overencapsulated caffeine Drug
- technetium Radiation
- placebo Drug
Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 23, 2009
- Primary completion
- Jul 14, 2010
- Completion
- Jul 14, 2010
- Last update posted
- Dec 2, 2024
2009 – 2010
United States locations
- U.S. sites
- 25
- U.S. states
- 15
- U.S. cities
- 25
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35294 | — |
| Not listed | Huntsville | Alabama | 35801 | — |
| Not listed | La Mesa | California | 91942 | — |
| Not listed | Mission Viejo | California | 92691 | — |
| Not listed | Roseville | California | 95661 | — |
| Not listed | Sacramento | California | 95819 | — |
| Not listed | Santa Rosa | California | 95405 | — |
| Not listed | Hartford | Connecticut | 06102-5037 | — |
| Not listed | Newark | Delaware | 19173 | — |
| Not listed | Jacksonville | Florida | 32216 | — |
| Not listed | Miami | Florida | 33173 | — |
| Not listed | Tamarac | Florida | 33321 | — |
| Not listed | Aurora | Illinois | 60504 | — |
| Not listed | Overland Park | Kansas | 66209 | — |
| Not listed | Auburn | Maine | 04210 | — |
| Not listed | Pittsfield | Massachusetts | 01201 | — |
| Not listed | Detroit | Michigan | 48202 | — |
| Not listed | Ypsilanti | Michigan | 48197 | — |
| Not listed | Kansas City | Missouri | 64111 | — |
| Not listed | Albany | New York | 12205 | — |
| Not listed | Rochester | New York | 14642-8679 | — |
| Not listed | Columbus | Ohio | 43214 | — |
| Not listed | Philadelphia | Pennsylvania | 19102 | — |
| Not listed | Wyomissing | Pennsylvania | 19610 | — |
| Not listed | Knoxville | Tennessee | 37920 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00826280, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 2, 2024 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00826280 live on ClinicalTrials.gov.